First AD

Second AD

Early-Stage vs Advanced CKD Treatment

What treatment options are available for patients in early-stage versus advanced CKD, and how should they be tailored to the patient's condition

What is the mechanism of action of nonsteroidal MRAs, such as finerenone, and how do they compare to other treatments?

Enhancing CKD Care in Type 2 Diabetes: Bridging Gaps in Diagnosis, Treatment, and Patient Outcomes

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Early-stage chronic kidney disease (CKD) management focuses on lifestyle modifications, blood pressure control, and glycemic management to slow progression. Advanced CKD requires more intensive interventions, including dialysis or transplantation. Treatment should be individualized based on the patient's comorbidities and disease progression. Nonsteroidal mineralocorticoid receptor antagonists (MRAs) like finerenone work by blocking mineralocorticoid receptors, reducing inflammation and fibrosis in the kidneys. They offer a novel approach compared to traditional treatments, potentially providing better cardiovascular and renal outcomes, especially in patients with diabetic kidney disease.

Panelists discuss the treatment options available for patients with early-stage versus advanced chronic kidney disease (CKD) and how these options should be tailored to individual patient conditions, as well as the mechanism of action of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone and their comparison to other treatment modalities.